The British journal of cardiologySep 10, 2026

Using GLP-1 receptor activators in heart disease: guidance for heart doctors

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 11, 2026

Abstract

Weight loss of over 10% is required to improve rates of major adverse cardiovascular events.

Obesity is linked to nearly all cardiovascular diseases, including heart failure and atrial fibrillation.
Reduction in weight is associated with significant improvements in blood pressure and blood sugar control.
GLP-1 receptor agonists show notable benefits in managing type 2 diabetes and obesity.
These medications may offer cardiovascular benefits, suggesting a key role in treating obesity-related cardiovascular diseases.
The review summarizes available GLP-1-based treatments and recent trials highlighting their cardiovascular advantages.

Simplified

Obesity is a global epidemic, which, directly and indirectly, contributes to almost all cardiovascular diseases, including atherosclerotic cardiovascular disease, heart failure and atrial fibrillation. Reduction of weight is associated with substantial improvements in cardiometabolic risk factors, including blood pressure and glycaemic control, with over 10% weight loss required to see improvement in rates of major adverse cardiovascular events. Glucagon-like peptide-1 (GLP-1) receptor agonists have changed the landscape of type 2 diabetes and obesity management, showing significant benefit in glycaemic control and weight loss. Their potential for cardiovascular benefits means that they will likely have a central role in the management of patients with obesity-related cardiovascular diseases. This review summarises currently available GLP-1-based pharmacotherapies and highlights recent trials demonstrating cardiovascular benefits, and also provides practical guidance for patient selection, available agents, their initiation and patient monitoring. This will serve as an aid for cardiovascular clinicians, who will inevitably encounter patients suitable for, or already using, these drugs in their daily practice.

Using GLP-1 receptor activators in heart disease: guidance for heart doctors

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief